VB 10.16

Drug Profile

VB 10.16

Alternative Names: VB10.16

Latest Information Update: 11 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Vaccibody
  • Class Cancer vaccines; DNA vaccines
  • Mechanism of Action Antigen-presenting-cell-modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Cervical intraepithelial neoplasia

Most Recent Events

  • 26 Apr 2018 Immunogenicity data from the phase I/II trial in Cervical intraepithelial neoplasia released by Vaccibody
  • 24 Jan 2018 Vaccibody completes enrolment in its phase I trial for Cervical intraepithelial neoplasia in Germany (NCT02529930)
  • 25 Oct 2016 Vaccibody in-licenses needle free injection technology from PharmaJet
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top